This was originally published in the Financial Times on Sunday, May 17, 2020.
We must not send the wrong message to pharma companies that have taken huge risks
As we confront an unprecedented public health, social and economic crisis brought about by Covid-19, our hopes are pinned on scientific innovation and, in particular, potential treatments and vaccines.
While we have good reason to hope science will prevail, there is understandable concern about how the fruits of innovation will be shared equitably and whether the pharmaceuticals industry can be trusted to put public health ahead of private profits. Some point to previous pandemics and warn that, unless deliberate steps are taken, the most vulnerable people will be left out.
Read more here.